Osteoporosis International

, Volume 22, Issue 6, pp 1855–1862 | Cite as

Skeletal health in men with chronic lung disease: rates of testing, treatment, and fractures

  • N. E. Morden
  • S. D. Sullivan
  • B. Bartle
  • T. A. Lee
Original Article

Abstract

Summary

To advance our understanding of the burden of fractures among men, we studied a group of men at high risk for low bone strength due to lung disease. We found high rates of fractures but low rates of bone density testing that could predict fracture before it occurs.

Introduction

To advance understanding of the burden of fragility fractures and attention to bone health among men with chronic obstructive lung disease (COPD), we quantified rates of fragility fracture, bone density testing, and anti-resorptive treatment and calculated the number needed to screen (NNS) to prevent one hip fracture in a cohort of men with COPD.

Methods

Veterans Administration (VA) and VA–Medicare administrative data permitted a retrospective cohort study of 87,360 men aged 50 and older, newly diagnosed with COPD between 1999 and 2003. Logistic regression models including patient characteristics, morbidities, and medication use assessed the effect of covariates on fracture and probability of testing or treatment.

Results

Mean age was 66.8. Hip and wrist fracture rates were 3.99 and 1.31 per 1,000 person years, respectively. Mean follow-up was 2.67 years; 4.4% underwent bone densitometry; 2.8% filled anti-resorptive prescriptions. Age, white race/ethnicity, more COPD exacerbations, barbiturate use, and anti-Parkinson’s drug use were significantly associated with fracture. Age, and systemic corticosteroids were most significantly associated with testing or treatment. Based on published adherence and treatment effects, the cohort’s calculated NNS to prevent one hip fracture is 432.

Conclusions

Fracture rate was high and testing and treatment uncommon. The NNS of 432 to prevent one hip fracture is smaller than 731, the NNS for women aged 65–69 for whom universal screening is recommended. Attention to the bone health of this population is warranted. Future research must determine how testing and treatment impact overall quality of life and mortality of men with COPD.

Keyword

Osteoporosis Prevention Pulmonary disease 

References

  1. 1.
    Bass E, French DD, Bradham DD, Rubenstein LZ (2007) Risk-adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol 17(7):514–519PubMedCrossRefGoogle Scholar
  2. 2.
    Braithwaite RS, Col NF, Wong JB (2003) Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 51(3):364–370PubMedCrossRefGoogle Scholar
  3. 3.
    Haentjens P, Lamraski G, Boonen S (2005) Costs and consequences of hip fracture occurrence in old age: an economic perspective. Disabil Rehabil 27(18–19):1129–1141PubMedCrossRefGoogle Scholar
  4. 4.
    Johnell O, Kanis JA (2004) An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15(11):897–902PubMedCrossRefGoogle Scholar
  5. 5.
    Khasraghi FA, Lee EJ, Christmas C, Wenz JF (2003) The economic impact of medical complications in geriatric patients with hip fracture. Orthopedics 26(1):49–53, discussion 53PubMedGoogle Scholar
  6. 6.
    Biskobing DM (2002) COPD and osteoporosis. Chest 121(2):609–620PubMedCrossRefGoogle Scholar
  7. 7.
    Iqbal F, Michaelson J, Thaler L, Rubin J, Roman J, Nanes MS (1999) Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function. Chest 116(6):1616–1624PubMedCrossRefGoogle Scholar
  8. 8.
    Dam TT, Harrison S, Fink HA, Ramsdell J, Barrett-Connor E (2009) Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos Int 21:1341–1349PubMedCrossRefGoogle Scholar
  9. 9.
    Vestergaard P, Rejnmark L, Mosekilde L (2007) Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest 132(5):1599–1607PubMedCrossRefGoogle Scholar
  10. 10.
    Sin DD, Man JP, Man SF (2003) The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 114(1):10–14PubMedCrossRefGoogle Scholar
  11. 11.
    Lekamwasam S, Trivedi DP, Khaw KT (2005) An association between respiratory function and hip bone mineral density in older men: a cross-sectional study. Osteoporos Int 16(2):204–207PubMedCrossRefGoogle Scholar
  12. 12.
    Jorgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V (2007) The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med 101(1):177–185PubMedCrossRefGoogle Scholar
  13. 13.
    Shane E, Silverberg SJ, Donovan D et al (1996) Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med 101(3):262–269PubMedCrossRefGoogle Scholar
  14. 14.
    Papaioannou A, Parkinson W, Ferko N et al (2003) Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporos Int 14(11):913–917PubMedCrossRefGoogle Scholar
  15. 15.
    Li L, Brennan KJ, Gaughan JP, Ciccolella DE, Kuzma AM, Criner GJ (2008) African Americans and men with severe COPD have a high prevalence of osteoporosis. COPD 5(5):291–297PubMedCrossRefGoogle Scholar
  16. 16.
    Barr RG, Celli BR, Mannino DM et al (2009) Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 122(4):348–355PubMedCrossRefGoogle Scholar
  17. 17.
    Franco CB, Paz-Filho G, Gomes PE et al (2009) Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of vitamin D. Osteoporos Int 20:1881–1887PubMedCrossRefGoogle Scholar
  18. 18.
    Carter JD, Patel S, Sultan FL et al (2008) The recognition and treatment of vertebral fractures in males with chronic obstructive pulmonary disease. Respir Med 102(8):1165–1172PubMedCrossRefGoogle Scholar
  19. 19.
    Penrod JD, Litke A, Hawkes WG et al (2008) The association of race, gender, and comorbidity with mortality and function after hip fracture. J Gerontol A Biol Sci Med Sci 63(8):867–872PubMedGoogle Scholar
  20. 20.
    Vestergaard P, Rejnmark L, Mosekilde L (2007) Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int 18(12):1583–1593PubMedCrossRefGoogle Scholar
  21. 21.
    de Luise C, Brimacombe M, Pedersen L, Sorensen HT (2008) Chronic obstructive pulmonary disease and mortality following hip fracture: a population-based cohort study. Eur J Epidemiol 23(2):115–122PubMedCrossRefGoogle Scholar
  22. 22.
    Leech JA, Dulberg C, Kellie S, Pattee L, Gay J (1990) Relationship of lung function to severity of osteoporosis in women. Am Rev Respir Dis 141(1):68–71PubMedGoogle Scholar
  23. 23.
    McKnight J, Scott A, Menzies D, Bourbeau J, Blais L, Lemiere C (2005) A cohort study showed that health insurance databases were accurate to distinguish chronic obstructive pulmonary disease from asthma and classify disease severity. J Clin Epidemiol 58(2):206–208PubMedCrossRefGoogle Scholar
  24. 24.
    Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG (2009) Identification and validation of vertebral compression fractures using administrative claims data. Med Care 47(1):69–72PubMedCrossRefGoogle Scholar
  25. 25.
    Curtis JR, Taylor AJ, Matthews RS et al (2009) “Pathologic” fractures: should these be included in epidemiologic studies of osteoporotic fractures? Osteoporos Int 20:1969–1972PubMedCrossRefGoogle Scholar
  26. 26.
    Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV (2009) New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res 44(5 Pt 1):1640–1661PubMedCrossRefGoogle Scholar
  27. 27.
    Sawka AM, Papaioannou A, Adachi JD, Gafni A, Hanley DA, Thabane L (2005) Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 6:39PubMedCrossRefGoogle Scholar
  28. 28.
    Nelson HD, Helfand M, Woolf SH, Allan JD (2002) Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137(6):529–541PubMedGoogle Scholar
  29. 29.
    Hansen KE, Swenson ED, Baltz B, Schuna AA, Jones AN, Elliott ME (2008) Adherence to alendronate in male veterans. Osteoporos Int 19(3):349–356PubMedCrossRefGoogle Scholar
  30. 30.
    Melton LJ 3rd, Crowson CS, O’Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9(1):29–37PubMedCrossRefGoogle Scholar
  31. 31.
    Ettinger B, Black D, Dawson-Hughes B, Pressman A, Melton JL (2010) Updated fracture incidence rates for US version of FRAX. Osteoporos Int 21:25–33PubMedCrossRefGoogle Scholar
  32. 32.
    Jorgensen NR, Schwarz P (2008) Osteoporosis in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 14(2):122–127PubMedCrossRefGoogle Scholar
  33. 33.
    Daniell HW (1972) Osteoporosis and smoking. JAMA 221(5):509PubMedCrossRefGoogle Scholar
  34. 34.
    Lewiecki EM, Gordon CM, Baim S et al (2008) International society for clinical densitometry 2007 adult and pediatric official positions. Bone 43(6):1115–1121PubMedCrossRefGoogle Scholar
  35. 35.
    Lim LS, Hoeksema LJ, Sherin K (2009) Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med 36(4):366–375PubMedCrossRefGoogle Scholar
  36. 36.
    National Osteoporosis Foundation (2008) The clinician’s guide to prevention and treatment of osteoporosis. http://www.nof.org/professionals/clinicians_guide.htm. Accessed June 17, 2009
  37. 37.
    Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK (2008) Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 148(9):680–684PubMedGoogle Scholar
  38. 38.
    Affairs VDCPGUSDoV (2007) Management of Chronic Obstructive Pulmonary Disease (COPD). http://www.healthquality.va.gov/Chronic_Obstructive_Pulmonary_Disease_COPD.asp. Accessed August 27, 2010
  39. 39.
    Piette JD, Heisler M (2004) Problems due to medication costs among VA and non-VA patients with chronic illnesses. Am J Manage Care 10(11 Pt 2):861–868Google Scholar
  40. 40.
    Department of Veterans Affairs (2010) Federal benefits for veterans, dependents & survivors. http://www1.va.gov/opa/publications/benefits_book/federal_benefits.pdf. Accessed August 26

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2010

Authors and Affiliations

  • N. E. Morden
    • 1
    • 2
    • 3
  • S. D. Sullivan
    • 4
  • B. Bartle
    • 5
  • T. A. Lee
    • 6
  1. 1.The Department of Community and Family MedicineDartmouth Medical SchoolHanoverUSA
  2. 2.The Dartmouth Institute for Health Policy and Clinical PracticeLebanonUSA
  3. 3.VA White River Junction Rural Health Research Center—Eastern RegionLebanonUSA
  4. 4.Department of Pharmacy, Pharmaceutical Outcomes Research and Policy ProgramUniversity of WashingtonSeattleUSA
  5. 5.Hines VA Medical CenterHinesUSA
  6. 6.Hines VA Hospital, Center for Management of Complex Chronic, Institute for Health Research and PolicyUniversity of Illinois at ChicagoChicagoUSA

Personalised recommendations